Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
Synucleinopathies represent a group of neurodegenerative disorders which are characterized by intracellular accumulation of aggregated α-synuclein. α-synuclein misfolding and oligomer formation is considered a major pathogenic trigger in these disorders. Therefore, targeting α-synuclein species repr...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-07-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnins.2018.00452/full |
id |
doaj-2898da8c04024017a7becfdb91e83dea |
---|---|
record_format |
Article |
spelling |
doaj-2898da8c04024017a7becfdb91e83dea2020-11-24T22:10:05ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2018-07-011210.3389/fnins.2018.00452375219Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of SynucleinopathyMartin Kallab0Marcos Herrera-Vaquero1Malin Johannesson2Fredrik Eriksson3Jessica Sigvardson4Werner Poewe5Gregor K. Wenning6Eva Nordström7Nadia Stefanova8Division of Neurobiology, Department of Neurology, Innsbruck Medical University, Innsbruck, AustriaDivision of Neurobiology, Department of Neurology, Innsbruck Medical University, Innsbruck, AustriaBioArctic AB, Stockholm, SwedenBioArctic AB, Stockholm, SwedenBioArctic AB, Stockholm, SwedenDivision of Neurobiology, Department of Neurology, Innsbruck Medical University, Innsbruck, AustriaDivision of Neurobiology, Department of Neurology, Innsbruck Medical University, Innsbruck, AustriaBioArctic AB, Stockholm, SwedenDivision of Neurobiology, Department of Neurology, Innsbruck Medical University, Innsbruck, AustriaSynucleinopathies represent a group of neurodegenerative disorders which are characterized by intracellular accumulation of aggregated α-synuclein. α-synuclein misfolding and oligomer formation is considered a major pathogenic trigger in these disorders. Therefore, targeting α-synuclein species represents an important candidate therapeutic approach. Our aim was to analyze the biological effects of passive immunization targeting α-synuclein and to identify the possible underlying mechanisms in a transgenic mouse model of oligodendroglial α-synucleinopathy. We used PLP-α-synuclein mice overexpressing human α-synuclein in oligodendrocytes. The animals received either antibodies that recognize α-synuclein or vehicle. Passive immunization mitigated α-synuclein pathology and resulted in reduction of total α-synuclein in the hippocampus, reduction of intracellular accumulation of aggregated α-synuclein, particularly significant in the spinal cord. Lowering of the extracellular oligomeric α-synuclein was associated with reduction of the density of activated iba1-positive microglia profiles. However, a shift toward phagocytic microglia was seen after passive immunization of PLP-α-synuclein mice. Lowering of intracellular α-synuclein was mediated by autophagy degradation triggered after passive immunization in PLP-α-synuclein mice. In summary, the study provides evidence for the biological efficacy of immunotherapy in a transgenic mouse model of oligodendroglial synucleinopathy. The different availability of the therapeutic antibodies and the variable load of α-synuclein pathology in selected brain regions resulted in differential effects of the immunotherapy that allowed us to propose a model of the underlying mechanisms of antibody-aided α-synuclein clearance.https://www.frontiersin.org/article/10.3389/fnins.2018.00452/fullimmunotherapyα-synucleinautophagyanimal modelα-synuclein clearance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Martin Kallab Marcos Herrera-Vaquero Malin Johannesson Fredrik Eriksson Jessica Sigvardson Werner Poewe Gregor K. Wenning Eva Nordström Nadia Stefanova |
spellingShingle |
Martin Kallab Marcos Herrera-Vaquero Malin Johannesson Fredrik Eriksson Jessica Sigvardson Werner Poewe Gregor K. Wenning Eva Nordström Nadia Stefanova Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy Frontiers in Neuroscience immunotherapy α-synuclein autophagy animal model α-synuclein clearance |
author_facet |
Martin Kallab Marcos Herrera-Vaquero Malin Johannesson Fredrik Eriksson Jessica Sigvardson Werner Poewe Gregor K. Wenning Eva Nordström Nadia Stefanova |
author_sort |
Martin Kallab |
title |
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_short |
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_full |
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_fullStr |
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_full_unstemmed |
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_sort |
region-specific effects of immunotherapy with antibodies targeting α-synuclein in a transgenic model of synucleinopathy |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neuroscience |
issn |
1662-453X |
publishDate |
2018-07-01 |
description |
Synucleinopathies represent a group of neurodegenerative disorders which are characterized by intracellular accumulation of aggregated α-synuclein. α-synuclein misfolding and oligomer formation is considered a major pathogenic trigger in these disorders. Therefore, targeting α-synuclein species represents an important candidate therapeutic approach. Our aim was to analyze the biological effects of passive immunization targeting α-synuclein and to identify the possible underlying mechanisms in a transgenic mouse model of oligodendroglial α-synucleinopathy. We used PLP-α-synuclein mice overexpressing human α-synuclein in oligodendrocytes. The animals received either antibodies that recognize α-synuclein or vehicle. Passive immunization mitigated α-synuclein pathology and resulted in reduction of total α-synuclein in the hippocampus, reduction of intracellular accumulation of aggregated α-synuclein, particularly significant in the spinal cord. Lowering of the extracellular oligomeric α-synuclein was associated with reduction of the density of activated iba1-positive microglia profiles. However, a shift toward phagocytic microglia was seen after passive immunization of PLP-α-synuclein mice. Lowering of intracellular α-synuclein was mediated by autophagy degradation triggered after passive immunization in PLP-α-synuclein mice. In summary, the study provides evidence for the biological efficacy of immunotherapy in a transgenic mouse model of oligodendroglial synucleinopathy. The different availability of the therapeutic antibodies and the variable load of α-synuclein pathology in selected brain regions resulted in differential effects of the immunotherapy that allowed us to propose a model of the underlying mechanisms of antibody-aided α-synuclein clearance. |
topic |
immunotherapy α-synuclein autophagy animal model α-synuclein clearance |
url |
https://www.frontiersin.org/article/10.3389/fnins.2018.00452/full |
work_keys_str_mv |
AT martinkallab regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT marcosherreravaquero regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT malinjohannesson regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT fredrikeriksson regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT jessicasigvardson regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT wernerpoewe regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT gregorkwenning regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT evanordstrom regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT nadiastefanova regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy |
_version_ |
1725809436650373120 |